Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217422 · ClinicalTrials.gov registry record · Phase 2
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT03217422 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT03217422, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
VAY736 dose testing; VAY736 efficacy and safety testing.
Interventions
- OTHER Placebo
- BIOLOGICAL VAY736
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-02-15 |
| Est. Completion | 2025-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03217422
The ClinicalTrials.gov registry entry for NCT03217422 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03217422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03217422 about?
NCT03217422 is a clinical study titled "ADCC Mediated B-Cell dEpletion and BAFF-R Blockade". VAY736 dose testing; VAY736 efficacy and safety testing.
What is the current status of trial NCT03217422?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2018-02-15. Estimated completion is 2025-12-17.
What interventions are being tested in trial NCT03217422?
The interventions under investigation include: Placebo (OTHER), VAY736 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03217422?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.